219 related articles for article (PubMed ID: 28199679)
1. Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.
Janes HE; Cohen KW; Frahm N; De Rosa SC; Sanchez B; Hural J; Magaret CA; Karuna S; Bentley C; Gottardo R; Finak G; Grove D; Shen M; Graham BS; Koup RA; Mulligan MJ; Koblin B; Buchbinder SP; Keefer MC; Adams E; Anude C; Corey L; Sobieszczyk M; Hammer SM; Gilbert PB; McElrath MJ
J Infect Dis; 2017 May; 215(9):1376-1385. PubMed ID: 28199679
[TBL] [Abstract][Full Text] [Related]
2. Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy.
Lhomme E; Richert L; Moodie Z; Pasin C; Kalams SA; Morgan C; Self S; De Rosa SC; Thiébaut R
PLoS One; 2016; 11(4):e0152952. PubMed ID: 27124598
[TBL] [Abstract][Full Text] [Related]
3. Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial.
Li SS; Gilbert PB; Carpp LN; Pyo CW; Janes H; Fong Y; Shen X; Neidich SD; Goodman D; deCamp A; Cohen KW; Ferrari G; Hammer SM; Sobieszczyk ME; Mulligan MJ; Buchbinder SP; Keefer MC; DeJesus E; Novak RM; Frank I; McElrath MJ; Tomaras GD; Geraghty DE; Peng X
J Virol; 2019 Nov; 93(21):. PubMed ID: 31434737
[TBL] [Abstract][Full Text] [Related]
4. Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.
Fong Y; Shen X; Ashley VC; Deal A; Seaton KE; Yu C; Grant SP; Ferrari G; deCamp AC; Bailer RT; Koup RA; Montefiori D; Haynes BF; Sarzotti-Kelsoe M; Graham BS; Carpp LN; Hammer SM; Sobieszczyk M; Karuna S; Swann E; DeJesus E; Mulligan M; Frank I; Buchbinder S; Novak RM; McElrath MJ; Kalams S; Keefer M; Frahm NA; Janes HE; Gilbert PB; Tomaras GD
J Infect Dis; 2018 Mar; 217(8):1280-1288. PubMed ID: 29325070
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk.
Moodie Z; Dintwe O; Sawant S; Grove D; Huang Y; Janes H; Heptinstall J; Omar FL; Cohen K; De Rosa SC; Zhang L; Yates NL; Sarzotti-Kelsoe M; Seaton KE; Laher F; Bekker LG; Malahleha M; Innes C; Kassim S; Naicker N; Govender V; Sebe M; Singh N; Kotze P; Lazarus E; Nchabeleng M; Ward AM; Brumskine W; Dubula T; Randhawa AK; Grunenberg N; Hural J; Kee JJ; Benkeser D; Jin Y; Carpp LN; Allen M; D'Souza P; Tartaglia J; DiazGranados CA; Koutsoukos M; Gilbert PB; Kublin JG; Corey L; Andersen-Nissen E; Gray GE; Tomaras GD; McElrath MJ
J Infect Dis; 2022 Aug; 226(2):246-257. PubMed ID: 35758878
[TBL] [Abstract][Full Text] [Related]
6. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
Kibuuka H; Kimutai R; Maboko L; Sawe F; Schunk MS; Kroidl A; Shaffer D; Eller LA; Kibaya R; Eller MA; Schindler KB; Schuetz A; Millard M; Kroll J; Dally L; Hoelscher M; Bailer R; Cox JH; Marovich M; Birx DL; Graham BS; Michael NL; de Souza MS; Robb ML
J Infect Dis; 2010 Feb; 201(4):600-7. PubMed ID: 20078213
[TBL] [Abstract][Full Text] [Related]
7. DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8
Li SS; Kochar NK; Elizaga M; Hay CM; Wilson GJ; Cohen KW; De Rosa SC; Xu R; Ota-Setlik A; Morris D; Finak G; Allen M; Tieu HV; Frank I; Sobieszczyk ME; Hannaman D; Gottardo R; Gilbert PB; Tomaras GD; Corey L; Clarke DK; Egan MA; Eldridge JH; McElrath MJ; Frahm N;
Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28931520
[TBL] [Abstract][Full Text] [Related]
8. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.
Koup RA; Roederer M; Lamoreaux L; Fischer J; Novik L; Nason MC; Larkin BD; Enama ME; Ledgerwood JE; Bailer RT; Mascola JR; Nabel GJ; Graham BS; ;
PLoS One; 2010 Feb; 5(2):e9015. PubMed ID: 20126394
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R
J Virol; 2021 Apr; 95(9):. PubMed ID: 33568510
[TBL] [Abstract][Full Text] [Related]
10. Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study.
Huang Y; Duerr A; Frahm N; Zhang L; Moodie Z; De Rosa S; McElrath MJ; Gilbert PB
PLoS One; 2014; 9(11):e108631. PubMed ID: 25369172
[TBL] [Abstract][Full Text] [Related]
11. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
12. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
Laher F; Moodie Z; Cohen KW; Grunenberg N; Bekker LG; Allen M; Frahm N; Yates NL; Morris L; Malahleha M; Mngadi K; Daniels B; Innes C; Saunders K; Grant S; Yu C; Gilbert PB; Phogat S; DiazGranados CA; Koutsoukos M; Van Der Meeren O; Bentley C; Mkhize NN; Pensiero MN; Mehra VL; Kublin JG; Corey L; Montefiori DC; Gray GE; McElrath MJ; Tomaras GD
PLoS Med; 2020 Feb; 17(2):e1003038. PubMed ID: 32092060
[TBL] [Abstract][Full Text] [Related]
13. Antigenic competition in CD4
Kallas EG; Grunenberg NA; Yu C; Manso B; Pantaleo G; Casapia M; Baden LR; Valencia J; Sobieszczyk M; Van Tieu H; Allen M; Hural J; Graham BS; Kublin J; Gilbert PB; Corey L; Goepfert PA; McElrath MJ; Johnson RP; Huang Y; Frahm N
Sci Transl Med; 2019 Nov; 11(519):. PubMed ID: 31748227
[TBL] [Abstract][Full Text] [Related]
14. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
[TBL] [Abstract][Full Text] [Related]
15. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
[TBL] [Abstract][Full Text] [Related]
16. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
Churchyard GJ; Morgan C; Adams E; Hural J; Graham BS; Moodie Z; Grove D; Gray G; Bekker LG; McElrath MJ; Tomaras GD; Goepfert P; Kalams S; Baden LR; Lally M; Dolin R; Blattner W; Kalichman A; Figueroa JP; Pape J; Schechter M; Defawe O; De Rosa SC; Montefiori DC; Nabel GJ; Corey L; Keefer MC;
PLoS One; 2011; 6(8):e21225. PubMed ID: 21857901
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
Graham BS; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Martin JE; McCluskey MM; Chakrabarti BK; Lamoreaux L; Andrews CA; Gomez PL; Mascola JR; Nabel GJ;
J Infect Dis; 2006 Dec; 194(12):1650-60. PubMed ID: 17109336
[TBL] [Abstract][Full Text] [Related]
18. Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.
Zhao LP; Fiore-Gartland A; Carpp LN; Cohen KW; Rouphael N; Fleurs L; Dintwe O; Zhao M; Moodie Z; Fong Y; Garrett N; Huang Y; Innes C; Janes HE; Lazarus E; Michael NL; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Robb ML; De Rosa SC; Corey L; Gray GE; Seaton KE; Yates NL; McElrath MJ; Frahm N; Tomaras GD; Gilbert PB
PLoS One; 2020; 15(1):e0226803. PubMed ID: 31999736
[TBL] [Abstract][Full Text] [Related]
19. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection.
Hemachandra A; Puls RL; Sirivichayakul S; Kerr S; Thantiworasit P; Ubolyam S; Cooper DA; Emery S; Phanuphak P; Kelleher A; Ruxrungtham K
Hum Vaccin; 2010 Oct; 6(10):835-40. PubMed ID: 20864808
[TBL] [Abstract][Full Text] [Related]
20. HLA-I Associated Adaptation Dampens CD8 T-Cell Responses in HIV Ad5-Vectored Vaccine Recipients.
Boppana S; Sterrett S; Files J; Qin K; Fiore-Gartland A; Cohen KW; De Rosa SC; Bansal A; Goepfert PA
J Infect Dis; 2019 Oct; 220(10):1620-1628. PubMed ID: 31301135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
